NIS2 for pharmaceutical and life-sciences organizations.
Pharma falls under NIS2 Annex II (important entities) as part of critical manufacturing. Matproof bridges NIS2 Art. 21 with existing GxP (GMP, GLP, GCP) IT controls, Annex 11 GMP validation, and medical-device cybersecurity expectations.
Why this matters now
Ransomware has hit multiple European pharma manufacturers in 2023-2025 with production disruption and regulatory scrutiny. NIS2 codifies cybersecurity expectations that EMA inspections are already applying de facto.
- GxP systems (LIMS, MES, ERP) often run on legacy platforms hard to patch and monitor
- Production-floor IT/OT convergence creates new attack surfaces not addressed by GMP alone
- Clinical-trial data security overlaps GDPR, GCP, and NIS2 — triple obligation
- Medical-device cybersecurity (IVDR/MDR) for combination products runs parallel to NIS2
How Matproof covers NIS2 for Pharmaceuticals & Life Sciences
GxP / NIS2 dual mapping
GAMP 5 principles + Annex 11 GMP IT validation + NIS2 Art. 21 in one control library. Validation evidence satisfies both audit regimes.
OT/ICS segmentation
Production-floor systems require segmentation, monitoring, and change-management aligned with both GMP and NIS2. Matproof integrates with OT security tooling to pull relevant evidence.
Clinical-trial data flow mapping
GCP requires audit trails for clinical data; NIS2 requires security; GDPR requires DPIA. All three into one record of processing with regulatory cross-references.
Supply chain: API + CDMO + IT
API suppliers, contract manufacturers (CDMOs), and IT/cloud vendors all fall under NIS2 Art. 21(2)(d). Matproof's vendor register maps tier, GxP audit status, and NIS2 risk posture in one view.
In scope
- Pharmaceutical manufacturers (human and veterinary medicines)
- Active pharmaceutical ingredient (API) producers
- Clinical trial sponsors and CROs
- Medical device manufacturers under MDR/IVDR with software/connectivity
- Biologics, advanced therapies (ATMPs), gene therapy developers
Frequently asked questions
Is my pharma company an essential or important entity under NIS2?+
Pharmaceutical manufacturers fall under NIS2 Annex II (important entities) at size thresholds of 50 employees or EUR 10M turnover. Large pharma meeting >250 FTE or >EUR 50M triggers the same important-entity status — not essential — because pharma is Annex II. Supervision is reactive rather than proactive compared to Annex I sectors.
How does NIS2 relate to GMP Annex 11?+
Annex 11 is the GMP guidance for computerized systems used in GxP-regulated manufacturing. NIS2 is broader cyber obligation. The overlap: validated IT systems under Annex 11 already have strong control structures (access, audit trails, change management, backup, DR). NIS2 adds: supply-chain security, board accountability, incident notification to BSI, training obligations, encryption requirements. Matproof maps GAMP 5 principles and Annex 11 IT controls to NIS2 Art. 21.
Do clinical trial systems need to meet NIS2?+
If your organization is NIS2-regulated, yes — clinical trial systems that process data or support operations fall under the same controls. The practical complication: CROs and eClinical vendors bring their own compliance posture. NIS2 Art. 21(2)(d) requires assessing their security, alongside GCP inspection readiness.
Related resources
Ready to start with NIS2?
30-minute demo tailored to Pharmaceuticals & Life Sciences. We show you exactly how Matproof covers NIS2 for your sector.